Onderneming SELLAS Life Sciences Group, Inc.
Aandelen
SLS
US81642T2096
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,24 USD | +2,48% | -23,93% | +16,98% |
Vakgebied
Aantal werknemers: 16
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Angelos Stergiou
FOU | Founder | 48 | 03-04-06 |
John Burns
DFI | Director of Finance/CFO | 39 | 01-05-13 |
Andrew Elnatan
LAW | General Counsel | - | 05-01-23 |
Dragan Cicic
PRN | Corporate Officer/Principal | 60 | 10-02-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 67 | 29-12-17 | |
David Scheinberg
BRD | Director/Board Member | 68 | 01-12-17 |
John Varian
BRD | Director/Board Member | 64 | 29-12-17 |
Jane Wasman
CHM | Chairman | 67 | 29-12-17 |
Angelos Stergiou
FOU | Founder | 48 | 03-04-06 |
Katherine Kalin
BRD | Director/Board Member | 61 | 13-08-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 56 267 670 | 55 984 386 ( 99,50 %) | 0 | 99,50 % |
Bedrijfsgegevens
SELLAS Life Sciences Group, Inc.
Times Square Tower 7 Times Square
10026, New York
+
http://www.sellaslifesciences.comSector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,98% | 69,77 mln. | |
-3,46% | 102 mld. | |
+1,41% | 96,09 mld. | |
+2,13% | 22,28 mld. | |
-15,84% | 21,4 mld. | |
-10,23% | 18,14 mld. | |
-39,98% | 17,02 mld. | |
-14,65% | 16,09 mld. | |
+4,39% | 13,83 mld. | |
+31,35% | 11,97 mld. |